Ranbaxy Laboratories Limited, India's largest pharmaceutical company, headquartered in India, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. It is ranked amongst the top ten generic companies worldwide. The Company has manufacturing operations in 7 countries with a ground presence in 49 countries and its products are available in over 125 countries.
Ranbaxy was incorporated in 1961 and went public in 1973. For the twelve months ended December 31, 2005, the Company's Global Sales were at US $1178 Mn. The Company's largest market USA with the sales of US $ 328Mn, accounted for 28%, while Europe and BRIC (Brazil, Russia, India, China) countries contributed 17% and 29% to global sales.
Ranbaxy has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe with a presence in Top 10 pharma markets of the world such as USA, Japan, Germany, France, UK, Italy, Spain, Canada, China, and Mexico along with strong operations in India, Brazil and South Africa. Additionally it has a presence in 21 of the 25 EU countries. While Ranbaxy aggressively pursues its internationalization strategy, it focuses equally on growth through the enhancement of its market share in India. A strong market presence and a significant distribution network give the company an edge over its competition. A balanced geographical presence coupled with a strong product flow from a wide therapeutic range serve as the business building blocks of the Company.
Research & Development (R&D)
Ranbaxy is among the few Indian pharmaceutical companies in India to recognize the importance of Research & Development (R&D) and invest early in it. The first basic research activity was initiated way back in the year 1973. Later when Ranbaxy drew its ambitious...